Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Officials Investigate UK Strains Showing Worrying Mutation

Tue, 02nd Feb 2021 17:26

(Alliance News) - Public Health England is investigating strains of coronavirus in the UK which have developed a mutation that has been worrying scientists.

Eleven cases in the Bristol area have been identified as the variant that originally arose in Kent but are now showing the E484K mutation.

A cluster of 32 cases in Liverpool also have the same mutation but relate to the original strain of coronavirus that has been around since the start of the pandemic.

The South African variant – which also shows the mutation – is under investigation in at least eight postcode areas of England where cases not linked to travel have been found.

A PHE spokesman said: "PHE is monitoring the situation closely and all necessary public health interventions are being undertaken, including enhanced contact tracing and control measures."

The E484K mutation has been shown to reduce the effectiveness of vaccines in preventing people contracting Covid-19.

However, public health experts believe current vaccines will still be effective against strains with the mutation, although at a lower level, and are good at preventing severe disease.

Earlier, Health Secretary Matt Hancock said testing was now under way in postcode areas affected by the mutation, alongside eight postcode areas affected by the South African variant.

Speaking in the Commons, Hancock said the government is working closely with pharmaceutical firms in case vaccines need to be tweaked to accommodate new variants.

He said: "We're working with pharmaceutical companies and with the scientists to understand both whether the such modifications are needed, where they are needed, and how they can be brought to use on the frontline as quickly and safely as possible.

"This is obviously a very important consideration given the new variants that we've seen.

"And we have confidence that modifications to vaccines, should they be necessary in large scale, will be available more quickly than the original vaccines.

"And just as we did first time round, when we got in there early and we bought at risk, so we are having exactly the same conversations right now with the pharmaceutical companies to make sure that we are right at the front of this one."

Hancock told MPs that the aim of community testing for the South African variant – currently targeting around 80,000 people in eight postcode areas – is to "stop its spread altogether".

He said: "As with the variant first identified here in the UK, there is currently no evidence to suggest it is any more severe but we have to come down on it hard.

"Our mission must be to stop its spread altogether and break those chains of transmission."

Regarding the E484K mutation seen in the Kent variant, Jonathan Stoye, from the Francis Crick Institute, said the PHE report suggests the UK variant is now independently acquiring the E484K change.

"From a virological standpoint, appearance of new variants by mutation during replication cannot be considered surprising," he added.

"Whether this change will provide significant growth advantages for the novel virus causing it to predominate remains to be seen."

Julian Tang, honorary associate professor at the University of Leicester, described the finding as "a worrying development, though not entirely unexpected".

He said it is important that people follow lockdown rules to prevent opportunities for the virus to mutate further, suggesting that allowing spread could provide a "melting pot" for different emerging variants.

"We really need to reduce our contact rates to reduce the opportunities for viral spread (and) replication to reduce the speed with which these different virus variants can evolve," he added.

Clinical trials for two coronavirus vaccines – Novavax Inc and Johnson & Johnson – have shown the jabs offer some protection against variants with the E484K mutation.

However, they are less effective than against the variant that has been around since the start of the pandemic.

Laboratory studies also suggest vaccines developed by Moderna Inc and Pfizer Inc/BioNtech SE could work against variants, while variant checks against the Oxford University/AstraZeneca vaccine are ongoing.

Earlier, Andrew Hayward, professor of infectious disease epidemiology at University College London and a member of the Scientific Advisory Group for Emergencies, said a "sustainable strategy" will be needed in the future to tackle coronavirus mutations.

He said that, while it is sensible to try to stamp out chains of transmission of variants, new strains will continue to be a risk and suggested borders cannot stay shut forever.

Asked on Sky News about the probability of more strains entering the UK unless borders are closed completely, or unless all people entering the country are forced into hotel quarantine for 14 days, Hayward said: "Well, probably in the long term, 100%.

"The nature of this virus is that it will continue to mutate, as do all viruses, and new strains will emerge and they'll emerge in many different countries in the world at different times, and you won't notice that they are spreading until such time as they are quite widespread.

"The real challenge here is that, well, yes, you can think about completely shutting the borders or having quarantine, (but) what's the endgame in that?

"Is that something that you're going to do forever, because it looks like these strains may continue to arise in the long term?

"So we need some sort of sustainable strategy, and I think that's very difficult for politicians to think about that."

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.